SkinBioTherapeutics plc (LON:SBTX – Get Free Report)’s stock price reached a new 52-week low during trading on Wednesday. The stock traded as low as GBX 5 and last traded at GBX 5.35, with a volume of 1044465 shares. The stock had previously closed at GBX 5.50.
SkinBioTherapeutics Price Performance
The company has a debt-to-equity ratio of 11.77, a current ratio of 6.14 and a quick ratio of 10.01. The stock has a market capitalization of £13.86 million, a price-to-earnings ratio of -33.41 and a beta of 0.10. The stock has a 50 day moving average price of GBX 9 and a 200-day moving average price of GBX 9.57.
About SkinBioTherapeutics
SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study.
Featured Stories
- Five stocks we like better than SkinBioTherapeutics
- Penguin Solutions Is Soaring as AI Memory Demand Explodes
- Alphabet’s Chart Is Coiling—and the Fundamentals May Be Ready to Back It Up
- Morgan Stanley Is Bullish on Apple—But With a Catch
- Disney Is Opening the Door to Netflix—and Changing the Streaming Playbook
Receive News & Ratings for SkinBioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SkinBioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
